All In Biotech

Drug Trial Radar · NCT01131676

BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).

A Phase III, Multicentre, International, Randomised, Parallel Group, Double Blind Cardiovascular Safety Study of BI 10773 (10 mg and 25 mg Administered Orally Once Daily) Compared to Usual Care in Type 2 Diabetes Mellitus Patients With Increased Cardiovascular Risk

Last checked: Nov 19, 2026Latest source record: May 16, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 7,064 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

7,064

Actual

Start

Jul 2010

Primary completion

Apr 2015

Study completion Apr 2015

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
Collaborators
Eli Lilly and Company
First posted
May 27, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of the present study is to investigate the safety of BI 10773 treatment in patients with Type 2 Diabetes Mellitus and high cardiovascular risk.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • BI 10773 low doseDrug

    BI 10773 tablets once daily

  • Placebo BI 10773 high doseDrug

    Placebo tablets identical to BI 10773

  • BI 10773 high doseDrug

    BI 10773 tablets once daily

  • Placebo BI 10773 low doseDrug

    Placebo tablets identical to BI 10773

  • Placebo BI 10773 low doseDrug

    Placebo tablets identical to BI 10773

  • Placebo BI 10773 high doseDrug

    Placebo tablets identical to BI 10773

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to the First Occurrence of Any of the Following Adjudicated Components of the Primary Composite Endpoint (3-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), and Non-fatal Stroke.Time frame: From randomisation to individual end of observation, up to 4.6 years

Locations

615 sites in 42 countries. Site status is shown where the registry gives one.

  • 1245.25.10043 Boehringer Ingelheim Investigational Site

    Birmingham, Alabama

  • 1245.25.10121 Boehringer Ingelheim Investigational Site

    Birmingham, Alabama

  • 1245.25.10037 Boehringer Ingelheim Investigational Site

    Huntsville, Alabama

  • 1245.25.10124 Boehringer Ingelheim Investigational Site

    Mobile, Alabama

  • 1245.25.10015 Boehringer Ingelheim Investigational Site

    Little Rock, Alaska

  • 1245.25.10056 Boehringer Ingelheim Investigational Site

    Gilbert, Arizona

  • 1245.25.10175 Boehringer Ingelheim Investigational Site

    Peoria, Arizona

  • 1245.25.10072 Boehringer Ingelheim Investigational Site

    Phoenix, Arizona

  • 1245.25.10048 Boehringer Ingelheim Investigational Site

    Harrisburg, Arkansas

  • 1245.25.10035 Boehringer Ingelheim Investigational Site

    Anaheim, California

  • 1245.25.10103 Boehringer Ingelheim Investigational Site

    Encino, California

  • 1245.25.10158 Boehringer Ingelheim Investigational Site

    Fresno, California

  • 1245.25.10126 Boehringer Ingelheim Investigational Site

    Harbor City, California

  • 1245.25.10058 Boehringer Ingelheim Investigational Site

    Huntington Park, California

  • 1245.25.10001 Boehringer Ingelheim Investigational Site

    Lancaster, California

  • 1245.25.10102 Boehringer Ingelheim Investigational Site

    Los Angeles, California

  • 1245.25.10047 Boehringer Ingelheim Investigational Site

    Los Gatos, California

  • 1245.25.10118 Boehringer Ingelheim Investigational Site

    Palm Springs, California

  • 1245.25.10061 Boehringer Ingelheim Investigational Site

    Riverside, California

  • 1245.25.10040 Boehringer Ingelheim Investigational Site

    San Diego, California

  • 1245.25.10055 Boehringer Ingelheim Investigational Site

    San Diego, California

  • 1245.25.10193 Boehringer Ingelheim Investigational Site

    San Diego, California

  • 1245.25.10027 Boehringer Ingelheim Investigational Site

    Santa Rosa, California

  • 1245.25.10074 Boehringer Ingelheim Investigational Site

    Stockton, California

  • 1245.25.10083 Boehringer Ingelheim Investigational Site

    Valencia, California

  • 1245.25.10144 Boehringer Ingelheim Investigational Site

    Colorado Springs, Colorado

  • 1245.25.10085 Boehringer Ingelheim Investigational Site

    Denver, Colorado

  • 1245.25.10153 Boehringer Ingelheim Investigational Site

    Denver, Colorado

  • 1245.25.10066 Boehringer Ingelheim Investigational Site

    Norwalk, Connecticut

  • 1245.25.10038 Boehringer Ingelheim Investigational Site

    Waterbury, Connecticut

  • 1245.25.10068 Boehringer Ingelheim Investigational Site

    Washington D.C., District of Columbia

  • 1245.25.10094 Boehringer Ingelheim Investigational Site

    Bradenton, Florida

  • 1245.25.10190 Boehringer Ingelheim Investigational Site

    Brooksville, Florida

  • 1245.25.10209 Boehringer Ingelheim Investigational Site

    Clearwater, Florida

  • 1245.25.10212 Boehringer Ingelheim Investigational Site

    Cooper City, Florida

  • 1245.25.10200 Boehringer Ingelheim Investigational Site

    Delray Beach, Florida

  • 1245.25.10033 Boehringer Ingelheim Investigational Site

    Fort Lauderdale, Florida

  • 1245.25.10202 Boehringer Ingelheim Investigational Site

    Hallandale, Florida

  • 1245.25.10062 Boehringer Ingelheim Investigational Site

    Hialeah, Florida

  • 1245.25.10063 Boehringer Ingelheim Investigational Site

    Hialeah, Florida

Showing 40 of 615 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.